Payer News
January 2020

Study shows improved outcomes in MDD using HAM-D6 scale

Published in BMC Psychiatry, Dunlop et al. evaluated whether the 6-item Hamilton Depression Rating Scale (HAM-D6) showed significant differences in outcomes for patients with major depressive disorder (MDD) who received the GeneSight test versus treatment as usual (TAU).

Using data from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized controlled trial, Dunlop et al. found:

  • HAM-D6 scale noted statistically significant improvements for all three clinical endpoints at week 8 when comparing the GeneSight group to TAU
    • symptoms (Δ=4.4%, p=0.023)
    • response (Δ=7.0%, p=0.004)
    • remission (Δ=4.6%, p=0.031)

Figure 1. Patients who received the GeneSight test had significantly improved clinical outcomes by week 8 (HAM-D6)

Dunlop Figure (002)
  • Patients taking medications predicted to have gene-drug interactions at baseline showed even greater improvement in symptoms, response, and remission at week 8 when using HAM-D6

GeneSight Information for Insurance Providers

Note: Not all patients who receive the GeneSight Psychotropic test will experience improvements in symptoms, achieve response, or achieve remission.

Myriad, the Myriad logo, and GeneSight are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2020 Myriad Genetic Laboratories, Inc.

Changing lives through genetic insight

Myriad Genetic Laboratories, Inc. 320 Wakara Way Salt Lake City UT 84108 United States

You received this email because you are subscribed to Marketing Information from Myriad Genetic Laboratories, Inc..
Update your email preferences or unsubscribe.